



# Lyfgenia in Saudi Arabia

*The SFDA cross-border QTC referral pathway — indicative 2026*

RARE DISEASE · LENTIVIRAL GENE THERAPY SCD

## The clinical situation

Lyfgenia (lovotibeglogene autotemcel) is a one-time infusion of lentiviral-vector-modified autologous haematopoietic stem cells introducing a functional  $\beta$ A-T87Q globin gene for severe sickle cell disease. Developed by bluebird bio. Treatment involves mobilisation, apheresis, a multi-week manufacturing window, myeloablative conditioning, infusion, and extended inpatient engraftment recovery at an authorised Qualified Treatment Centre. Boxed warning: haematologic malignancy risk; long-term haematologic surveillance is mandated.

### The pathway, 5 steps

- 1 Consultation & eligibility.** Haematologist confirms severe SCD diagnosis, crisis history, organ-system baseline, boxed-warning counselling, and fitness for myeloablative conditioning.
- 2 QTC referral.** Reserve Meds coordinates cross-border referral to a Lyfgenia-qualified centre via our international care-coordination network.
- 3 SFDA / MoH medical-referral dossier.** Your physician files the cross-border referral with rationale, QTC identification, and the long-term surveillance plan.
- 4 Mobilisation, apheresis & manufacturing.** Conducted at the QTC; several-week manufacturing window; bridging transfusion support locally or at the QTC.
- 5 Conditioning, infusion & engraftment.** QTC inpatient stay 4–6+ weeks; handover to your Saudi haematologist for mandated long-term haematologic surveillance.

### Indicative economics

**Reference US list price:** USD 3.0–3.2M one-time for the gene-therapy product; total cost of care at a US QTC typically runs substantially higher (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**12–24 weeks** from intake to infusion, driven by the manufacturing window and QTC calendar. Inpatient stay 4–6+ weeks. Indicative — not guaranteed.

## Reserve Meds's role

**QTC referral.** Coordination with authorised Lyfgenia centres through our clinical network. **Documentation.** Cross-border referral and SFDA/MoH named-patient package, including long-term-surveillance plan. **Logistics.** Patient and caregiver travel, prayer-space and halal-dining orientation at the QTC, and post-infusion return-home planning. **Concierge case lead.** Named point of contact throughout the treatment journey and the long-term surveillance period. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Lyfgenia × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/lyfgenia-saudi-arabia.html](https://reservemed.com/access-guides/lyfgenia-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team